Invokana (Canagliflozin) and Weight Loss
Invokana (Canagliflozin) and weight loss
Canagliflozin has been shown to reduce weight in type 2 diabetic patients who are obese. Obesity is when a person has excessive body fat. Obesity is a risk factor for type 2 diabetes. When you are obese, your body becomes less sensitive to insulin. This leads to higher amounts of blood glucose. If left untreated, this can contribute to type 2 diabetes. If you are overweight and you are diagnosed with type 2 diabetes, you can take this medicine to help control your blood sugar and it may also assist in weight loss. Researchers found that non-diabetic people who took invokana at doses of 50mg, 100mg or 300mg once daily, had greater weight reductions compared to those who took the placebo. In addition to weight reduction, canagliflozin showed significant reduction in Body Mass Index (BMI) compared to the placebo. This medication is believed to contribute to weight loss because calories are lost with increased glucose excretion via urine.
Disclaimer: Please note that the contents of this community article are strictly for informational purposes and should not be considered as medical advice. This article, and other community articles, are not written or reviewed for medical validity by Canadian Insulin or its staff. All views and opinions expressed by the contributing authors are not endorsed by Canadian Insulin. Always consult a medical professional for medical advice, diagnosis, and treatment.